注射用重组人脑利钠肽联合呋塞米注射液治疗急性心力衰竭患者的临床疗效观察

Clinical efficacy of recombinant human brain natriuretic peptide for injection combined with furosemide injection in the treatment of patients with acute heart failure

目的探讨注射用重组人脑利钠肽联合呋塞米注射液治疗急性心力衰竭患者的临床疗效。方法100例急性心力衰竭患者,随机分为观察组与对照组,每组50例。对照组患者接受呋塞米注射液治疗,观察组患者在对照组基础上联合注射用重组人脑利钠肽治疗。比较两组患者心功能相关生化指标[脑利钠肽(BNP)、血肌酐(SCR)、血钾(K^(+))、血钠(Na^(+))]、疗效及不良反应发生情况。结果治疗7 d后,观察组患者BNP(835.54±105.64)ng/L、SCR(108.65±18.20)μmol/L和Na^(+)(138.68±15.24)mmol/L低于对照组的(1358.14±115.03)ng/L、(135.05±11.87)μmol/L、(168.54±10.58)mmol/L,K^(+)(3.97±0.35)mmol/L高于对照组的(2.95±0.18)mmol/L,差异有统计学意义(P<0.05)。观察组患者治疗总有效率为92.00%,高于对照组的70.00%,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论采用注射用重组人脑利钠肽联合呋塞米注射液治疗急性心力衰竭,能够显著改善患者的临床症状和心功能水平,减低心功能受损程度,利于患者预后,且安全性与单一用药相似,不会增加不良反应发生风险,值得临床推广应用。

Objective To discuss the clinical efficacy of recombinant human brain natriuretic peptide for injection combined with furosemide injection in the treatment of patients with acute heart failure.Methods A total of 100 patients with acute heart failure were randomly divided into observation group and control group,with 50 cases in each group.Patients in the control group were treated with furosemide injection,and patients in the observation group were treated with recombinant human brain natriuretic peptide for injection on the basis of the control group.Both groups were compared in terms of cardiac function related biochemical indicators[brain natriuretic peptide(BNP),serum creatinine(SCR),serum potassium(K^(+)),serum sodium(Na^(+))],efficacy and occurrence of adverse reactions.Results After 7 d of treatment,the BNP(835.54±105.64)ng/L,SCR(108.65±18.20)μmol/L and Na^(+)(138.68±15.24)mmol/L of the observation group were lower than(1358.14±115.03)ng/L,(135.05±11.87)μmol/L,(168.54±10.58)mmol/L of the control group,and the K^(+)(3.97±0.35)mmol/L was higher than(2.95±0.18)mmol/L of the control group.All the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 92.00%,which was higher than 70.00%in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Recombinant human brain natriuretic peptide for injection combined with furosemide injection in the treatment of patients with acute heart failure can significantly improve the clinical symptoms and heart function level of patients,reduce the degree of heart function damage,benefit the prognosis of patients,and the safety is similar to that of single drug without increasing the risk of adverse reactions,so it is worthy of clinical promotion and application.